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Open access under CC BThe purpose of this study was to investigate if rapidly measured physical properties can predict glass- 
forming ability and glass stability of drug compounds. A series of 50 structurally diverse drug molecules 
were studied with respect to glass-forming ability and, for glass-formers (n = 24), the physical stability 
upon 1 month of storage was determined. Spray-drying and melt-cooling were used to produce the amor- 
phous material and the solid state was analysed by Differential Scanning Calorimetry (DSC) and Powder 
X-ray Diffraction. Thermal properties and molecular weight (Mw) were used to develop predictive mod- 
els of (i) glass-forming abil ity and (ii) physical stability. In total, the glass-forming ability was correctly 
predicted for 90% of the drugs from their Mw alone. As a rule of thumb, drugs with Mw greater than 
300 g/mole are expected to be transformed to its amorphous state by using standa rd process technology.
Glass transition temperat ure and Mw predicted the physical stability upon storage corr ectly for 78% of
the glass-formin g compounds. A strong sigmoidal relationship (R2 of 0.96) was identiﬁed between crys- 
tallization temperature and stability. These ﬁndings have the potential to rationalize decisions schemes 
for utili zing and developing amorphous formulations, through early predictions of glass-forming ability 
from Mw and physical stability from simple DSC characterization.
 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introductio n
When developing a dosage form for an active compound with 
poor solubility, preformulation data give rather unspeciﬁc infor- 
mation on what formulation strategies to apply (Branchu et al.,
2007; Kawabata et al., 2011 ). A higher degree of predictio n and 
precision in decision making would enable more efﬁcient drug 
product development and provide an early stage insight into the 
potential of solubility limited drug compounds to be processed into 
functional and stable dosage forms. In this context, it is necessary 
to develop methods that can predict the solid state behaviour of
drug compounds during processing and manufactur ing. Solid state 
alterations, in particular amorphization , often have signiﬁcant
inﬂuence on the performance of a substance, impacting for in- 
stance mechanical properties (Ziffels and Steckel, 2010 ), dissolu- 
tion (Lindfors et al., 2006; Murdand e et al., 2010 ) and 
bioavailabili ty (Hancock and Parks, 2000 ). Amorphization is hence 
a strategy with high potential to increase bioavaila bility of com- 
pounds for which poor solubility is limiting intestinal absorption.
However, as the inherent instability of the amorphous state limits harmacy, Uppsala University,
ppsala, Sweden. Tel.: +46 18
ahlin).
Y-NC-ND license.production, handling and use of products based on amorpho us
compounds , research efforts are currently directed towards meth- 
ods that stabilize the amorphous phase (Kearns et al., 2008; Laiti- 
nen et al., in press ). Fundamental aspects governing the physical 
stability, i.e. the resistance of an amorphous compound to be trans- 
formed into its crystalline state, has lately been in focus with the 
purpose to obtain an increased understa nding of the dynamics 
(Aso et al., 2001; Bhattacharya and Suryanar ayanan, 2009; Singh 
and de Pablo, 2011; Stukalin et al., 2009 ) and nucleation processes 
(Marsac et al., 2006; Vyazovki n and Dranca, 2007 ).
Thermodynam ically the physical stability is governed by the 
differenc e in Gibbs free energy between the amorphous and the 
crystalline states. Both nucleation rate and crystal growth is how- 
ever also affected by the dynamics, i.e. the molecular mobility, of
the amorpho us phase. The glass transition temperature (Tg) has 
therefore been used as a reference temperature when determining 
glass-for mation temperature s (Corrigan et al., 2004; Yamaguchi 
et al., 1992 ) and storage temperature s (Hancock et al., 1995;
Schoug et al., 2009 ). However, the predictive capacity of Tg for
physical stability has been shown to be poor, which is manifested,
by for instance, the observati on that compounds with similar Tg
may have different amorphous stability (Marsac et al., 2006 ), and 
that alteration s in amorphous stability attained by variations in
production settings not always are reﬂected in observable changes 
of Tg (Yamaguchi et al., 1992; Zhang et al., 2009 ).
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methodology to ﬁnd other physicochem ical propertie s that corre- 
late with glass-forming ability and glass stability. In these, the 
interest has been to predict and understand which compounds 
can be made stable amorphous based on the thermodyna mic and 
kinetic properties of the compounds. Greaser et al. made univariat e
correlation analysis of kinetic and thermod ynamic paramete rs to
assess storage stability of nine drug compounds and found conﬁg-
urational entropy to be the parameter that best described the sta- 
bility (Graeser et al., 2009 ). In another study, logistic regression 
analysis was used to ﬁnd that Tg and molecular volume combined 
predict glass-forming ability for a number of compounds when ex- 
posed to mechanical treatment (milling) (Lin et al., 2009 ). Taylor 
and co-worke rs have analysed a larger dataset of compounds 
(n = 51) by principal component analysis (PCA) and found that 
molecular properties (number of rotational bonds and molecular 
weight) are important, but also that thermal properties (heat of fu- 
sion, entropy of fusion, the free energy differenc e between the 
crystalline and amorphous states and melting temperat ure) need 
to be included to separate glass-for mers from poor glass-forming 
compounds (Baird et al., 2010 ). The same factors were found to
be important for discriminati ng fast, intermedi ate and slow crys- 
tallizers in a follow up study on physical stability of amorpho us
drugs (Van Eerdenbrugh et al., 2010 ). Although these attempts 
have identiﬁed some properties that likely will inﬂuence the stabil- 
ity of the amorpho us material, no conclusions have been reached 
on the understanding of the fundamenta l propertie s governing 
amorphous phase formation and stability of drug like compounds 
(Bhugra and Pikal, 2008 ).
Recently we have shown how statistical modelling by partial 
least squares projection to latent structure s discrimin ant analysis 
(PLS-DA) can be used to predict glass-forming ability of com- 
pounds from their molecular structure (Mahlin et al., 2011 ). The 
establishment of a model that used molecular descriptors reﬂect-
ing size, branching, distribution of electronega tive atoms, symme- 
try and number of benzene rings correctly predicted 75% of the 
compounds in an external test set. In the present work, we contin- 
ued to explore the inherent ability of pure drugs to form an amor- 
phous state in settings comparable to standard production 
conditions. A series of 50 structurally diverse drugs was investi- 
gated upon processing by spray-drying and melt-cooling. For the 
compounds thereby showing good glass-forming ability we further 
studied the inherent ability to remain in the amorpho us state upon 
storage. This resulted in two datasets; a dataset for the ability to
form the glass, in which the compounds were sorted as (i) glass- 
former or (ii) nonglass -former, and a dataset for the stability of
the formed material, in which the compound s (n = 24) were 
classed as (iii) stable glass or (iv) non-stable glass. The datasets 
were used together with experimental ly measured physical prop- 
erties to develop models predicting glass-forming ability and glass 
stability, applicable as preformulation tools in early drug 
developmen t.2. Methods 
2.1. Materials 
In this study, a dataset previously investiga ted for glass-forming 
ability (Mahlin et al., 2011 ), and for which most of the compounds 
display solid-state limited aqueous solubility, was extended with a
diverse set of molecule s to allow general conclusions to be drawn 
applicable to the drug-like space of oral drugs. In total 50 com- 
pounds were included in the ﬁnal dataset subjected to analysis of
properties of importance for glass-forming ability and glass stabil- 
ity (Table 1). All of the compound s studied were used in their free form, i.e. no salts of compounds were included. Differential Scan- 
ning Calorimetry (DSC) veriﬁed that the starting material was crys- 
talline and none of the compounds showed any traces of solvates.
Bicalutam ide, felodipine and linaprazan were received as a kind 
gift from AstraZeneca (Mölndal, Sweden) and acitretin was pur- 
chased from Ontario Chemicals (Canada). All the other drugs were 
obtained from Sigma–Aldrich Chemie GmbH (Germany). The spec- 
iﬁed purity of the drugs used was >98%, except for griseofulvin 
(>96%). Ethanol (Alita Corporat ion, Finland) and acetone (VWR
Internationa l S.A.S., France) were used as solvents in the spray-dry- 
ing feed solution.
2.2. Production and identiﬁcation of the amorphous form 
Two different methods , spray-drying and melt-cooling, were 
used to test the susceptibility of the compounds to be transformed 
into the amorphous form. Only the compounds for which both 
these methods resulted in the same outcome, i.e. formatio n of
either a crystalline or an amorphous solid, were included in the 
dataset that was utilized for statistical modelling. The dual produc- 
tion procedure was applied for two reasons. Firstly, the idea was to
identify the inherent glass-forming ability of the drug compound s
rather than the process depende nt glass-forming properties. Sec- 
ondly, we wanted to minimize the risk of false classiﬁcation that 
may be caused by hidden processes that affect the outcome, such 
as chemical degradation upon heating. Melt-cool ing was done in
DSC using unprocessed substance and spray-dryi ng by using solu- 
tions of the compounds as described in detail previously (Mahlin
et al., 2011 ). Brieﬂy, the solubility of each compound in a solvent 
mixture of ethanol and acetone (90:10 w/w) was determined by
preparin g a dispersion of the drug in the solvent mixture, which 
was subsequently stepwise diluted and sonicated until complete 
dissolution was observed. Solutions of the compounds at a concen- 
tration correspondi ng to 75% of the solubility were spray-dried in a
Büchi B-290-Mini Spray Dryer with an inert loop (Büchi Laborato -
riums, Switzerland) using a standardise d procedure with the fol- 
lowing settings: inlet temperature 50 C, pump rate of spray 
solution 4 ml/min, and aspirator rate 75% of the maximum ﬂow.
The produced material was dried over vacuum at room tempera- 
ture (22 C) for 1 h prior to solid state analysis.
The solid state of the spray-dried material was analysed by DSC 
(DSC6200, Seiko, Japan). The temperature and heat ﬂow was cali- 
brated using indium. Approxim ately 2 mg of each compound were 
weighed into aluminium pans (TA Instrument standard pan,
Waters, UK) with perforated lids and analysed using a heating rate 
of 20 C/min enabling full separation of crystallizati on and melting 
peaks. The analysis was run from 20 C to a temperature above the 
melting point of the compound (Tm) while being purged with nitro- 
gen gas (80 ml/min). No signs of residual solvents desorbing during 
heating was observed in the DSC signal. The presence of amor- 
phous phase in the samples was judged from the occurrence of
glass transition and exotherm ic crystallization peaks in the heat 
ﬂow signal upon heating, alternativel y a complete absence of crys- 
tallization and melting peaks. The glass transition was determined 
from the mid-point of the step change in heat ﬂow and the amor- 
phous content of the spray-dried compounds was estimated from:
%Amorphous ¼ DHcr
DH
100 ð1Þ
where DHcr is the enthalpy of crystalliza tion and calculated from 
area under the crystalliza tion peak in the thermogr am, and DH is
the difference in enthalpy between the amorphous and crystalline 
state at the crystalliza tion temperatu re (Tcr), and given by
DH ¼ DHm 
Z Tm
T
DCpdT ð2Þ
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and
DCp ¼ Camp  Ccrp ð3Þ
where Camp and C
cr
p are the heat capacities of the amorp hous and 
crystalline state, respective ly. As an approximat ion, DCp can be as- 
sumed to be constan t and calculate d according to Thompson and 
Spaepen (1979):
DCp ¼ DHmTm ð4Þ
where DHm and Tm is obtained from the DSC data.Table 1
Physicochemical and glass stability characteri stics of the compounds studied.
Compounds Tg (C) Tm (C) Tcr (C) DHm (J/g) DGcr (
Acemetacin 37 148 79 135 40
Acetohexamide 26 190 65 206 75
Albendazole a 60 202 56 202 77
Bezaﬁbrate 73a 184 61 176 62
Carbamazepine 61b 190 77 111 40
Felodipine 41 142 86 85 25
Griseofulvin 88 216 80 123 49
Nifedipine 45b 171 73 134 45
Testosterone 42 153 51 109 34
Bicalutamide 50 192 97 123 45
D-lactose 105 195 140 100 37
Famotidine 50 167 104 185 61
Glafenine 63 164 120 87 28
Glibenclamide 62 172 – 116 39
Hydrochlorothiazide 110 263 139 144 65
Hydrocortisone 86 211 123 118 46
Hydroﬂumethiazide 100 269 142 122 56
Indometacin 44 159 104 122 39
Linaprazan 100 246 147 148 64
Metolazone 109 266 – 109 49
Omeprazole 51 155 90 145 45
Pimozide 57b 216 106 100 40
Spironolactone 91 213 127 60 23
Warfarine 68 162 – 195 63
Bucetin 3a 158 159 50
Bufexamac 2a 167 93 31
Caffeine 72b 236 101 42
Chlorzoxazone 38b 190 161 58
Diﬂunisal 43a 213 175 69
D-mannitol 13
c 165 374 122 
Fenbufen 28a 186 202 72
Flumequine 78a 258 147 65
Hymecromone 9a 181 202 71
Indoprofen 50b 210 143 56
Mefenamic acid 51a 231 214 89
Naproxen 3a 153 157 49
Pindolol 14a 169 263 87
Primidone 72a 283 211 99
Probenecid 50a 199 153 57
Pyrazinecarboxamide 28a 188 209 75
Saccharin 20a 226 189 77
Salicylic acid 38a 158 205 65
Spiperone 106 a 207 162 62
Sulfamethoxazole 16a 169 156 52
Sulfanilamide 21a 164 175 57
Theophylline 94b 272 185 85
Tolfenamic acid 63b 212 144 56
Trimethoprim 51a 197 167 62
Tyramine 37a 161 262 84
Zoxazolamine 11 183 191 67
Glass transition temperature (Tg), onset temperature of melting (Tm), onset temperature o
(DGcr), entropy of melting (DSm) and molecular weight (Mw). Compounds showing detect
classiﬁed as glass-formers.
a Calculated according to Baird et al. (2010) (24).
b Value obtained from Baird et al. (2010) (24).
c Value from SciFinder (ACS).The solid state of the spray-dried material was further veriﬁed
by X-ray Powder Diffraction analysis. Diffraction patterns were ob- 
tained by using a Kratzky camera with a linear position-sen sitive 
wide angle detector (HECUS M. BRAUN X-ray Systems, Graz,
Austria) detecting diffracted radiation in a 2h interval from 17 to
25 (given by the limits of the detector) in steps of 0.01 . The radi- 
ation was generated by an Cu Ka X-ray generator (Philips, PW
1830/40) working at 40 V and 50 A. The temperature was con- 
trolled to 25 C by a Peltier element. Each sample was run for 
15 min in vacuum. When the X-ray analysis showed a diffuse scat- 
tering pattern the sample was considered to be predominantly 
amorpho us, while samples generating diffraction patterns with 
distinctiv e peaks were considered to contain crystalline phase.J/g) DSm (J/K/g) Mw (g/mol) Glass-former Stable on storage? 
0.32 415.8 Yes No
0.44 324.4 Yes No
0.43 265.3 Yes No
0.39 361.8 Yes No
0.24 236.3 Yes No
0.21 384.3 Yes No
0.25 352.8 Yes No
0.30 346.3 Yes No
0.26 288.4 Yes No
0.26 430.4 Yes Yes 
0.21 342.3 Yes Yes 
0.42 337.4 Yes Yes 
0.20 372.8 Yes Yes 
0.26 494.0 Yes Yes 
0.27 297.7 Yes Yes 
0.24 362.4 Yes Yes 
0.23 331.3 Yes Yes 
0.28 357.8 Yes Yes 
0.29 366.5 Yes Yes 
0.20 365.8 Yes Yes 
0.34 345.4 Yes Yes 
0.20 461.5 Yes Yes 
0.12 416.6 Yes Yes 
0.45 308.3 Yes Yes 
0.37 223.3 No –
0.21 223.3 No –
0.20 194.2 No –
0.35 169.6 No –
0.36 250.2 No –
0.85 182.2 No –
0.44 254.3 No –
0.28 261.2 No –
0.44 176.2 No –
0.30 281.3 No –
0.42 241.3 No –
0.37 230.3 No –
0.60 248.3 No –
0.38 218.3 No –
0.32 285.4 No –
0.45 123.1 No –
0.38 183.2 No –
0.48 138.1 No –
0.34 395.5 No –
0.35 253.3 No –
0.40 172.2 No –
0.34 180.2 No –
0.30 261.7 No –
0.36 290.3 No –
0.60 137.2 No –
0.42 168.6 No –
f crystallization (Tcr), enthalpy of melting (DHm), Gibb’s free energy of crystallization 
able amounts of amorphous phase directly after spray-drying and melt-cooling were 
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cooled from the pure liquid state was investiga ted by cooling melts 
of the drugs in the DSC. The experimental conditions were the 
same as for the analysis of spray-dried material, except that 
approximat ely 2 mg of unprocessed substance was weighed into 
the aluminium pans. The samples were analysed by performing 
two heating/coolin g cycles, the ﬁrst for melt-cooling and the sec- 
ond for analysis. During the ﬁrst cycle the samples were heated 
from room temperat ure to approximately 10 C above their Tm at
a heating rate of 20 C/min and immediatel y cooled at a rate of
40 C/min. To analyse the presence of an amorphous phase after 
the ﬁrst cycle, the second DSC cycle was performed in the same 
way as the DSC run to determine the amorphous content of the 
spray-dried material. No thermal events other than the expected 
glass transitions, crystallizations and melting, were observed in
the DSC signal upon heating of the material.
2.3. Dry stability of amorphous material 
The spray-dried material of the pure drug compound was put 
on short term storage to provide an indication of the dry stability 
of the glass-formers when kept in the glassy state, below their Tg.
Therefore, all compounds being partially or completely amorphous 
after spray-dryi ng were stored for 1 month in glass vials over silica 
gel in an evacuated desiccator at room temperature (22 C). The so- 
lid state of each compound was then analysed again by DSC apply- 
ing the same DSC protocol as used immediately after production.
The fraction of the amorphous phase that had been transformed 
into a crystalline state upon 1 month of storage (a) was calculated 
by
a ¼ 1  DH
stored 
cr
DHcr
ð5Þ
where DHstored cr is the heat of crystalliza tion of the solid after storage 
and DHcr the same as above, i.e. heat of crystalliza tion determine d
immediat ely after spray-dry ing.
2.4. Analyses of glass-forming ability and dry stability – relation to
physical properties 
The glass-forming ability and dry stability were analysed for 
their depende nce of the following measured physical properties 
which were obtained from DSC analysis of the unprocessed crystal- 
line material: Tm (onset of melting peak), DHm (melt enthalpy from 
melting peak area), DSm (entropy of melting) and DGcr (Gibbs free 
energy of crystallization at storage temperature), and analysis of
amorphous material obtained after spray-drying: Tg (the midpoint 
of the glass transition temperat ure) and Tcr (onset of crystallization 
temperature upon heating at 20 C/min). In addition, Mw, which 
previously has been identiﬁed as an important molecular property 
for glass-forming ability (Baird et al., 2010 ) and the following ad- 
justed properties were included: reduced Tg (Tg,red which is equal 
to the ratio Tg/Tm), Tm  Tg, (Tcr  Tg)/(Tm  Tg), DGcr  Tg,red, DGcr/
Tg,red, DGcr  Tg, DGcr/Tg, DGcr  Mw, DGcr/Mw, Tm  Mw, Tm/Mw,
Tg  Mw, Tg/Mw, Tg,red  Mw, Tg,red/Mw, Tcr  Tg, Tcr/Tg, Tcr  Mw,
Tcr/Mw, DGcr  Tcr and DGc/Tcr. These adjusted parameters were 
introduced to make possible the ﬁnding of relations between 
parameters that are non-linea rly interdependen t. An estimated va- 
lue of Tg was calculated for compounds for which Tg could not be
determined from the thermal analysis, using a procedure described 
by Baird et al. (2010). In short, the Tg,red of the compound s for 
which Tg had been experime ntally determined was plotted as a
function of Mw. A straight line was ﬁtted to the plot and thereby 
a theoretical Tg could be calculated from the obtained straight line 
equation.All the above described properties were included as variables 
and subjected to PLS-DA as implemented in Simca v.11 (Umet-
rics, Sweden). The following procedure was used to develop 
the classiﬁcation model of glass-forming ability: The computa- 
tional model for glass-forming ability (n = 50) was designed to
different iate between glass-for mers, i.e. compounds able to form 
an amorphous state from both spray-drying and melt-cooling 
(assigned value 1), and non-glass-for mers, i.e. compound s
remaining crystalline irrespect ive of production technology used 
(assigned value 1). This classiﬁcation neither took into account 
how much of the material that had become amorphous upon 
processin g nor whether the amorphous material was stable over 
time; only the ability to exist in the amorphous state after being 
subjected to the two material processing techniques was mod- 
elled. It should here be noted that the melt-quenchi ng and 
spray-dryi ng are two fundamentally different routes for solid for- 
mation, the former a transformation from the melted state and 
the latter from a solution. This should certify that we are study- 
ing the inherent glass-forming propensi ty of the drugs. The data- 
set was divided into training (2/3) and test (1/3) sets to allow 
assessme nt of general applicabi lity of the models developed.
Standard settings in Simca, including seven cross validation 
groups, were used.
The model for glass stability was devised to separate stable 
glasses, deﬁned as compounds which had retained more than 
50% of the amorpho us content after 1 month of storage (assigned
the value 1), from non-stabl e glasses deﬁned as compounds that 
lost more than 50% of the amorpho us content during this time per- 
iod (assigned value 1). Albendazole was excluded from the stabil- 
ity modelling due to its high crystalline content after production 
(82%) which possibly could obscure a correct analysis of the stabil- 
ity of the amorphous phase and hence increasing the risk of false 
classiﬁcation, Due to the small number of compound s (n = 23)
and that the number of compound s in the stable group (n = 15)
was large compared to the unstable group (n = 8), all the com- 
pounds were included in the model developmen t. To give the 
two groups equal weight, the unstable group was duplicated in
the input matrix used for PLS-DA, resulting in that informat ion 
from the same compound was repeated eight rows down in the 
matrix. This approach has been identiﬁed as suitable when 
modellin g signiﬁcantly different group sizes. In the model 
developmen t of dry stability the number of cross validation groups 
was set to eight in order to simultaneously leave both duplicates 
out in the cross-validati on of the model.
In the model developmen t for both glass-forming ability and 
stability, the data were mean centered and scaled to unit variance,
and variables that were skewed were excluded from the model 
developmen t to not distort the models. The models were devel- 
oped using the following schedule to allow as much information 
to be extracted as possible: (i) only thermodynam ic propertie s
(Tm, DHm, DSm, DGcr) were used as input variables (n = 4), (ii) to
matrix i, Tg related properties were added (n = 11) and (iii) to ma- 
trix ii, Mw related properties were added (n = 20). In the modelling 
of glass stability matrix iv was created by adding Tcr related prop- 
erties were to matrix iii (n = 29). From each starting point (i–iv) a
variable selection was performed in which input information that 
was not directly related to the response (i.e., noise) was removed,
and thereby the predictivity and robustness of the model was in- 
creased. The accuracy of the statistically signiﬁcant PLS-DA models 
was judged by how well the two classes of the training sets were 
separated from each other. In addition, for glass-forming ability,
once the selection of physical propertie s had been ﬁnalized the 
resulting models were validated with the test set.
To evaluate the models for glass stability, the fraction of the 
amorpho us phase that had been transformed into a crystalline 
state upon 1 month of storage (a) was plotted against Tg, Mw, Tcr
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on Tg and Mw. A sigmoidal relationship 
a ¼ 1  1ð1 þ eðT0TcrÞkÞ ð6Þ
was ﬁtted to the data points in the plots by adjustment of the shape 
factors T0 and k.
3. Results and discussion 
3.1. Preparation of amorpho us materials – glass-formi ng ability 
The results from the classiﬁcation of glass-forming ability of the 
50 compounds are presented in Table 1. For all compounds there 
was an agreement between DSC and X-ray data, as a clear crystal- 
lization peak visible in the thermogram upon heating in all cases 
coincided with a diffuse background scattering without diffraction 
peaks in X-ray. In the case of glibencla mide, metolazone and warf- 
arine, the absence of both a crystallization peak and a melting peak 
in the DSC thermogr am was taken as the sample being amorphous 
and stable upon heating. The X-ray analysis of these compounds 
conﬁrmed they being predominantly amorphous state. Albenda- 
zole and Nifedipine showed small crystallization peaks and estima- 
tions based on the DSC-data showed that were just partially 
amorphous (approximately 18% and 67%, respectivel y). Of the 50
compounds investigated , 26 were detected to be crystalline (no
amorphous phase detected) after both melt-cooling and spray-dry- 
ing whereas 24 showed partly or complete transformat ion to the 
amorphous form. Hence, the latter 24 were classiﬁed as glass- 
formers (see Table 1).
3.2. Stability of dry amorphous material 
After storage for 1 month, DSC-anal ysis showed that 15 of the 
glass-forme rs had preserved more than 50% of its amorphous con- 
tent (see Table 1). For 13 of these, the fraction crystallized was <5%
which is within the uncertainty of the crystallinity determination 
by this method. Bicalutamide and omepraz ole lost approximat ely 
11% and 36% of their amorphous content, respectively . For the 
compounds classiﬁed as unstable, no amorpho us phase could be
detected by DSC after storage, except for griseofulvin, felodipine 
and acemetacin, which according to our calculations had a crystal- 
linity of 95%, 79% and 56%, respectively, after storage.
3.3. Physical properties of importanc e for glass-formi ng ability of drugs 
In order to ﬁnd out if thermodyna mic properties could be used 
for predictio ns of glass-forming ability a PLS-DA was performed 
based on the thermodynam ic quantities Tm, DHm, DSm and DGcr.
These are easily measured by using a crystalline sample of a com- 
pound using standard DSC equipme nt. However, the PLS-DA mod- 
elling attempts resulted in non-signiﬁcant models (data not 
shown). In the next step, we therefore also included Tg-related
parameters, which are assumed to represent properties related to
the molecular mobility of the amorphous state. Interestingl y, the 
most predictiv e model, shown in Fig. 1, did not include any param- 
eter representing an absolute temperature paramete r (Tm or Tg), as
could be expected since the quality of the amorpho us product 
formed often are related to differenc e between formation temper- 
ature and Tg (Yamaguchi et al., 1992 ). Instead it was the balance 
between thermodyna mic and kinetic properties, i.e. the adjusted 
parameters involving both Tm and Tg, that carried most informa- 
tion. In this case, the predictivity was 81% for the test set 
(Fig. 1A). The model was based on Tg,red, Tm  Tg, DSm, DGcr  Tg,red,
DHm, DGcr/Tg,red and DGcr/Tg,red and hence, the analysis showed that the Tg-related properties indeed carry informat ion of importance 
for the prediction of glass-for ming ability.
In a general context, larger molecules are commonly less prone 
to crystallize from a liquid state (Baird et al., 2010 ). Therefore, we
wanted to evaluate the effect of Mw on the predictio ns and hence,
a new model was built including all former paramete rs, together 
with Mw-related properties. In this analysis, only the adjusted 
paramete r Tg,red  Mw remained after model reﬁnement and this 
property predicted 91% and 94% correctly of the training and test 
sets, respectivel y (Fig. 1B). We also found that equal predictivity 
was obtained from Mw alone (accuracy of training and test sets 
of 88% and 94%, respectively , Fig. 1C). The results obtained herein,
based on a large and structurally diverse drug-like dataset,
strengthen previous ﬁndings of the importance of molecula r size 
and Tg as predictors of glass-forming ability (Lin et al., 2009 ). In
the scientiﬁc discussion, it is often referred to Kauzman n (1948)
and Turnbull (1969) who suggested that compounds with a Tg,red
higher than 2/3 are good glass-formers. The theoretical rationale 
for this effect is that compound s with smaller super-cooled liquid 
regime (i.e. high Tg,red) have a lower probability for nucleation 
when cooled below its melting temperature due to less time spent 
in that critical region. This has been conﬁrmed in a study on a
homologous series of cyclic stilbenes (Ping et al., 2011 ), but in
the same publication it was argued not to be true when looking 
at more diverse chemical structures. Recently it was shown by
Baird et al., that for a set of drug compound s the Tg,red is not useful 
for predictin g glass-for ming ability (Baird et al., 2010 ). This is par- 
tially in line with our observation that Mw is a good predictor by
itself, and that the Tg,red contributes with minor information . This 
was further underlined by that Tg,red alone was a poor predictor 
(data not shown). We therefore propose that for compounds with 
a molecula r weight range corresponding to common poorly soluble 
drugs, propertie s relating to molecular size is the dominating fac- 
tor determining glass-forming ability, whereas for limited series 
of compound s with similar molecular weight, the Tg,red may be
more useful for predictions. Some publications highlight the role 
of the conﬁgurational entropy differenc e between the amorpho us
and crystalline state, and that compounds with higher Mw have 
more complex molecular structure and hence, are less likely to ex- 
ist in an ordered crystalline state (Bhugra and Pikal, 2008; Graeser 
et al., 2009; Zhou et al., 2002 ). Therefore, there seems to be a ra- 
tional behind using the Mw as an easily obtained surrogate for 
description of conﬁgurational entropy, although the latter property 
also is depende nt on other structural features, e.g. number of rotat- 
able bonds. Further, it has been suggested that the complexity 
associate d with larger molecules means that it has to probe a lar- 
ger number of possible conformations and conﬁgurations to ﬁnd
an ordered (crystalline) packing structure during solidiﬁcation
(Bhugra and Pikal, 2008 ). It is appealing to imagine the tendency 
of becoming either amorpho us or crystalline as being dependent 
on the molecula r process of probing the various possible conforma- 
tions and conﬁgurations (related the conﬁgurational space, and 
hence to the Mw of the compound) and the time available to ﬁnd
a conﬁguration that will produce an ordered crystal unit during 
solidiﬁcation (related to the Tg,red at constant cooling conditions).
In the present study, the dominating factor for glass-formatio n
seems to be Mw. In Fig. 2 the relation between Mw and glass-form- 
ing ability is visualized. From our analysis, based on a large struc- 
turally diverse dataset we suggest that compounds with Mw above 
300 g/mole are likely to be transformed to the correspondi ng glass 
using standard production/am orphization technolo gies, whereas 
compounds with Mw below this value will be difﬁcult to produce 
amorpho us. It should be kept in mind that we base this conclusion 
on compound s having a melting point higher than 140 C. How- 
ever, the general applicabi lity of this rule-of-thumb was conﬁrmed
by applying the analysis on the 51 compounds studied by Baird
(A)
(B)
(C)
(D)
Fig. 1. Accuracy of the prediction of the glass-forming ability for the training set and the test set used. Training set used for model development is shown as open squares, test 
set as ﬁlled circles. Glass-formers were given the value 1 and nonglass-formers (i.e. compounds remaining crystalline after being processed by both spray-drying and melt- 
cooling) were given the value 1. Observed glass forming ability is shown on the y-axis, predicted on the x-axis. (A) Model based on thermodynamic and kinetic glass 
properties. Remaining after model optimization were Tg,red, DHm, DSm, Tm  Tg, (DGcr/Tg,red), (DGcr/Tg), (DGcr  Tg,red). (B) Model obtained after adding Mw related properties to
the variable selection. Tg,red  Mw remained after variable selection. (C) Classiﬁcation obtained from Mw alone. (D) Classiﬁcation based on Tg,red alone.
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Fig. 2. Single correlation between glass-forming ability and molecular weight.
Based on the results from the 50 compounds studied herein a cut-off for Mw of 300 
is suggested for rapid prediction of glass-forming ability, with compounds having 
Mw > 300 mg/mole likely to be good glass-formers.
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sorted with regard to their glass-forming ability when using Mw of
300 g/mole as the cut-off value.3.4. Physical properties of importance for dry stability of amorphous 
drugs
In the same way as for glass-forming ability, the glass stability 
was analysed step-wis e. The thermodyna mic properties did, again,
not result in a signiﬁcant model for dry stability. The variable 
selection after including the Tg-related propertie s to the model 
developmen t resulted in that Tg was found to be the single most 
important property , and did by itself predict 65% of the compounds 
accurately (Fig. 3A). After inclusion of Mw the ﬁnal properties 
remaining after the variable selection were Tg and Mw and the 
predictivity increased to 78% (Fig. 3B). It should be noted that all 
Tg-values except one (bezaﬁbrate) used in stability modelling have 
been experimental ly determined.
Since no test set was available for validation, the stability mod- 
el developed was evaluated using the calculated fraction of the 
amorphous phase transformed during storage (a). A plot of a as
a function of the prediction values generate d by the model is dis- 
played in Fig. 4. This shows the model is not only able to separate 
the two classes stable and non-stabl e with 78% certainty, but also 
able to assign the lowest values (<0.5) for all the compounds 
that was fully crystallized upon storage, and highest values (>0)
for all the compound that did not crystallize during storage (the
only exception being griseofulvi n having high predictio n value 
but low stability). There seem to be a sigmoidal relation between 
the predicted values and a which further support the validity of
the model. The rational for why a model based on the paramete rs
Tg and Mw is able to predict glass stability can be deducted in a
similar way as for glass-forming ability, i.e. it is the balance be- 
tween the molecular mobility (the rate of molecula r motion)
and the conﬁgurational space (how many conﬁgurations that 
can be probed) that governs crystallization tendency of a com- 
pound. It has been shown that molecula r mobility determines 
the rate of crystallization of an amorphous phase when analysing 
the temperature dependency of single amorpho us compounds 
(Aso et al., 2001; Bhattachary a and Suryanarayanan, 2009; Bhugra 
et al., 2008 ). However, when it comes to comparing crystallization 
tendencies for a number of structura lly diverse compounds other 
factors has to be considered to predict physical stability (Van Eer- 
denbrugh et al., 2010 ) and one factor identiﬁed to be important is
the conﬁgurational entropy (Graeser et al., 2009; Zhou et al.,
2002). Based on this we hypothesize that Tg and Mw is describin gmolecula r mobility and conﬁgurational entropy well enough to,
when combined, be able to predict glass stability. It is interesting 
to note that the compound being poorest predicted by the Mw–
Tg-storage model, griseofulvi n, has been extensively studied as
to ﬁnd out the reason for its sensitivity to production conditions,
since its stability is higher when amorphisized by melt-cooling as
compare d to milling (34–36).3.5. Crystallizatio n temperature 
A glass heated above its Tg may crystallize before it reach the 
thermod ynamic melting temperature . The onset of this crystalliza- 
tion is dependent on the nucleation tendency and crystal growth 
rate of the heated amorphous system (Bhugra and Pikal, 2008;
Hancock and Zograf, 1997 ). At a well-deﬁned heating rate and 
sample size, the onset temperature of crystallization (Tcr) can be
regarded as an indicator of the crystallization tendency of the 
amorpho us compound. However, no evaluation of the capacity of
Tcr to predict storage stability for a number of relatively diverse 
drug compound s has so far been published. Since we in this study 
had information on physical stability of the amorphous phase upon 
storage below Tg we had an opportunity to study is relation to
Tcr. Hence, Tcr was included as an input paramete r and evaluated 
by the PLS-DA modelling. In the reﬁned model Tcr remained as
the only parameter, on its own giving the best predictivity, with 
95% accurate classiﬁcation of the compounds (Fig. 3C). To further 
evaluate this correlation a plot of a as a function of the Tcr was
done. As for the stability prediction model a strong sigmoidal rela- 
tionship (R2 of 0.96 upon ﬁtting to Eq. (6)) was obtained (see
Fig. 4). No clear outliers from this relation were found, indicative 
of that Tcr is able to capture the important factors that govern 
the physical stability of amorpho us compounds upon storage 
below Tg.
Although the relation between molecular mobility and crystal- 
lization of amorphous compounds below and above Tg has been 
studied previously (Bhugra et al., 2008; Caron et al., 2010 ), such 
a clear and simple correlation between Tcr and storage stability 
as the one observed here has, to the best of our knowledge, not 
been reported. Tcr has shown to be sensitive to the condition of
an amorphous material in terms of physical aging (Surana et al.,
2004) and pre-nucleat ion (Trasi et al., 2010; Wu and Yu, 2006 )
which in turn is dependent on the production setting and thermal 
history of the amorpho us phase. Hence, it seems logical that Tcr
better describes the stability than Mw and Tg, since the latter can 
be regarded more as intrinsic material properties. Therefore, it is
very likely that the Tcr better correlates to storage stability of amor- 
phous materials produced by different technologies and at differ- 
ent conditions. However, further studies are needed to conﬁrm
this assumption. From a prediction perspecti ve, the 78% accuracy 
obtained using Tg and Mw justify the usage of these properties to
predict the inherent glass stability of compounds in the early part 
of the drug developmen t process, since Tg may be estimated from 
calculatio ns (Baird et al., 2010 ) or simulations (Xiang and Ander- 
son, 2013 ) in silico . However, Tcr may more accurately foresee sta- 
bility later during the drug developmen t process, in particular 
during stages when decisions are to be made with regard to pre- 
ferred production technology for the amorphizat ion.
From the plot in Fig. 4, it is apparent that a compound with a Tcr
higher than 100 C is stable upon 1 month of storage at 22 C. This 
relation can also be expressed as that an amorphous compound has 
to be stored at no less than 80 C below its Tcr in order to be stable 
for 1 month, and is valid for Tcr-values determined at a heating rate 
of 20 C/min. However, the validity for other storage temperatures,
relative humidities and formulation s compositi ons must be further 
evaluated.
(A)
(B)
(C)
Fig. 3. Accuracy of the prediction of the glass stability for the training set used. Correctly predicted compounds are shown as black circles, falsely predicted in red.
Compounds being stable amorphous were given the value 1, whereas unstable compounds were given the value 1, and all experimental data obtained in this study was used 
in the analysis of properties of importance for amorphous stability. Observed glass stability is shown on the y-axis, predicted on the x-axis. (A) Model based on
thermodynamic and kinetic glass properties. Tg alone remained after variable selection. (B) Model obtained after adding Mw related properties to the variable selection. Final 
model obtained was based on Tg and Mw. (C) Model obtained after adding Tcr related properties to the variable selection. The ﬁnal model obtained was based on Tcr only.
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In this work we have studied a large series of structura lly di- 
verse compound s and from thermal analysis and multivariate data 
analysis identiﬁed important properties to forecast the inherent 
drug properties glass-forming ability and dry stability of the produced amorphous material. The glass-forming ability was 
shown to be well predicted from Mw alone. The results suggest 
that as a rule-of-thumb , drugs with Mw greater than 300 g/mol 
are expected to be transformed to its amorpho us state using stan- 
dard process technology. In addition, Mw together with Tg pre-
dicted the dry stability of 78% of the amorpho us drugs correctly.
Fig. 4. Storage stability as a function of single parameters and the predictive model. The calculated fraction of the amorphous compound that had transformed after 1 month 
of storage at 22 C and at dry conditions (a) plotted against Tcr (upper left), model predicted values based on Tg and Mw (upper right), Tg (lower left) and Mw (lower right). A
strong sigmoidal relationship (R2 of 0.96 upon ﬁtting of Eq. (6)) to glass stability was obtained for Tcr showing that all compounds having Tcr > 100 C being stable upon 
1 month of storage. The other plots are shown for comparison, with line representing sigmoidal relationship inserted as a guide to the eye.
D. Mahlin, C.A.S. Bergström / European Journal of Pharmaceutical Sciences 49 (2013) 323–332 331In this study we also identiﬁed a strong relationship between Tcr
and the dry stability of the amorphous drugs. In addition to inher- 
ent compound properties, Tcr is sensitive to structural changes in
an amorpho us phase of importance for its stability, thereby being 
more accurate for produced amorphous materials. Taken together 
the ﬁndings in this study show that early stage evaluations of
the inherent glass-forming ability of a compound can be made 
from Mw. For glass-forme rs, Mw together with calculated or sim- 
ulated Tg can be used to predict the storage stability of the amor- 
phous form of a drug. When an amorphous material has been 
produced we suggest that the Tcr can be used to evaluate and ratio- 
nalize the selection of production technology and optimal produc- 
tion settings. These properties, e.g. Mw, Tg and Tcr, have the 
potential to rationalize decision-ma king in drug developmen t as
they help judging the potential of a compound to be formulated 
amorphous.
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